ZSTK474

• CAT Number: I003653
• CAS Number: 475110-96-4
• Molecular Formula: C₁₉H₂₁F₂N₇O₂S
• Molecular Weight: 417.41
• Purity: ≥95%
• Target: PI3K
• Solubility: DMSO ≥20mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL
• Storage: 3 years -20℃ powder
• IC50: 37 nM [1]
• IUPAC Name: 4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]morpholine
• InChI: InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2
• InChIKey: HGVNLRPZOWWDKD-UHFFFAOYSA-N
• SMILES: C1COCCN1C2=NC(=NC(=N2)N3C4=CC=CC=C4N=C3C(F)F)N5CCOCC5

ZSTK474 (Cat.No:I003653) is a promising chemical compound with significant interest in the pharmaceutical industry. This compound exhibits potent inhibitory effects on phosphoinositide 3-kinase (PI3K), a key enzyme involved in cell growth and survival pathways. Research indicates that ZSTK474 may hold therapeutic potential against various diseases, making it an attractive target for further drug development.

Reference

[1]. Yaguchi S, et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst, 2006, 98(8), 545-556.
[2]. Kong D, et al. ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci, 2007, 98(10), 1638-1642.
[3]. Kong D, et al. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. Eur J Cancer, 2009, 45(5), 857-865.